Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists infect older adults with RSV to unlock vaccine secrets

NCT ID NCT03728413

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the immune system of older adults (ages 60-75) responds to a controlled infection with respiratory syncytial virus (RSV). Researchers gave 28 healthy volunteers a weakened form of the virus via nasal drops and monitored their symptoms and immune reactions for 14 days. The goal was to identify which parts of the immune response are most important for protection, which could guide the development of better RSV vaccines for the elderly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RSV A Memphis 37 (a weakened respiratory syncytial virus given as nasal drops)
What this could lead to
If successful, this study could reveal which immune targets are most important for protecting older adults against RSV, helping design better vaccines.
What could go wrong
This is a very small, early-stage study (28 participants) that deliberately infects people with a virus. It is not testing a treatment or vaccine, so direct benefits are unlikely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Nov 2018

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy persons aged 60 to 75 years, able to give informed consent * Non smokers or ex-smokers with smokers with less than or equal to 5 pack years smoking history. * Spirometry within the normal range for age and height (+/- 15%) * FEV1/FVC \>70% pre-bronchodilator Exclusion Criteria: * Chronic respiratory disease (asthma, COPD, rhinitis, sinusitis) in adulthood * Inhaled bronchodilator or steroid use within the last 12 months * Habitual use of any medication or other product (prescription or over-the-counter) for symptoms of rhinitis or nasal congestion within the last 3 months * Acute upper respiratory infection (URI or sinusitis) in the past 6 weeks * Subjects with allergic symptoms present at baseline * Clinically relevant abnormality on chest X-ray * Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, other elderly adults (\>65 years), immunosuppressed persons, or those with chronic respiratory disease * Subjects with known or suspected immune deficiency * Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to challenge * Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome * History of frequent nose bleeds * Any significant medical condition or prescribed drug deemed by the study doctor to make the participant unsuitable for the study * Women of childbearing potential must have a negative hCG urine pregnancy test \* * Positive urine drug screen * Women of childbearing potential will have a pregnancy test performed prior to virus inoculation to exclude pregnancy and be required to use contraception throughout the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Imperial College London

    London, W12 0NN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.